Status:
COMPLETED
Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.
Lead Sponsor:
Novartis Vaccines
Collaborating Sponsors:
Novartis
Conditions:
Meningococcal Meningitis
Eligibility:
All Genders
12-59 years
Phase:
PHASE2
Brief Summary
To compare the functional immune response 28 days after administration of one dose of Men ACWY-CRM conjugate vaccine without adjuvant (MenACWY-CRM(Ad-)) with that of a Men ACWY polysaccharide (PS) vac...
Eligibility Criteria
Inclusion
- healthy 12-\<60 month old children;
Exclusion
- subjects who have previously received any meningococcal vaccine
- subjects with any serious acute or chronic progressive disease
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2006
Estimated Enrollment :
623 Patients enrolled
Trial Details
Trial ID
NCT00310817
Start Date
March 1 2005
End Date
May 1 2006
Last Update
November 6 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Tampere Medical School
Tampere, Finland
2
Oddz. Neuroinfekcji, Szpital Jana Pawla II, Krakow
Samodzielny ZOZ, Lubartów, Poland